Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ATLAS
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
- NCT03991403 ↗
- Unknown
- Samsung Medical Center
- Focused
We haven't built an HCP commentary report on ATLAS yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ATLAS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Atezolizumab(Tecentriq); Pemetrexed; Bevacizumab; Carboplatin; Paclitaxel; Carboplatin or cisplatin
- Arms
- Atezolizumab group · Experimental
- Control group · Active comparator
- Enrollment
- 228
- Primary outcomes
- progression-free survival, PFS
- Sponsor
- Samsung Medical Center
- Start
- Aug 27, 2019
- Primary completion
- Mar 11, 2023
- Results posted
- No
- Registry record
- NCT03991403 · updated Apr 3, 2023
Publications
linked from the registry- Bang YH, Park GH, Oh JW, Hwang S, Jeong JG, Lee B, Joe CY, Kim H, Kim J, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Ahn CH, Ali SM, Ock CY, Lee SH. Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. J Immunother Cancer. 2025 Oct 31;13(10):e012374. doi: 10.1136/jitc-2025-012374. PubMed 41173494
- Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20. PubMed 37861993